Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma
Zhewen Xiong,Stephen Lam Chan,Jingying Zhou,Tsz Tung Kwong,Xuezhen Zeng,Haoran Wu,Jianquan Cao,Yalin Tu,Yu Feng,Weiqin Yang,Patrick Pak-Chun Wong,Willis Wai-Yiu Si-Tou,Xiaoyu Liu,Jing Wang,Wenshu Tang,Zhixian Liang,Jiahuan Lu,Ka Man Li,Jie-Ting Low,Michael Wing-Yan Chan,Ka-Fai To,Kevin Yuk-Lap Yip,Yuk Ming Dennis Lo,Joseph Jao-Yiu Sung,Alfred Sze-Lok Cheng,Joaquim S.L. Vong,Howard H.W. Leung,Anthony W.H. Chan
DOI: https://doi.org/10.1136/gutjnl-2022-328364
IF: 24.5
2023-04-05
Gut
Abstract:Objective Therapy-induced tumour microenvironment (TME) remodelling poses a major hurdle for cancer cure. As the majority of patients with hepatocellular carcinoma (HCC) exhibits primary or acquired resistance to antiprogrammed cell death (ligand)-1 (anti-PD-[L]1) therapies, we aimed to investigate the mechanisms underlying tumour adaptation to immune-checkpoint targeting. Design Two immunotherapy-resistant HCC models were generated by serial orthotopic implantation of HCC cells through anti-PD-L1-treated syngeneic, immunocompetent mice and interrogated by single-cell RNA sequencing (scRNA-seq), genomic and immune profiling. Key signalling pathway was investigated by lentiviral-mediated knockdown and pharmacological inhibition, and further verified by scRNA-seq analysis of HCC tumour biopsies from a phase II trial of pembrolizumab ( NCT03419481 ). Results Anti-PD-L1-resistant tumours grew >10-fold larger than parental tumours in immunocompetent but not immunocompromised mice without overt genetic changes, which were accompanied by intratumoral accumulation of myeloid-derived suppressor cells (MDSC), cytotoxic to exhausted CD8 + T cell conversion and exclusion. Mechanistically, tumour cell-intrinsic upregulation of peroxisome proliferator-activated receptor-gamma (PPARγ) transcriptionally activated vascular endothelial growth factor-A (VEGF-A) production to drive MDSC expansion and CD8 + T cell dysfunction. A selective PPARγ antagonist triggered an immune suppressive-to-stimulatory TME conversion and resensitised tumours to anti-PD-L1 therapy in orthotopic and spontaneous HCC models. Importantly, 40% (6/15) of patients with HCC resistant to pembrolizumab exhibited tumorous PPARγ induction. Moreover, higher baseline PPARγ expression was associated with poorer survival of anti-PD-(L)1-treated patients in multiple cancer types. Conclusion We uncover an adaptive transcriptional programme by which tumour cells evade immune-checkpoint targeting via PPARγ/VEGF-A-mediated TME immunosuppression, thus providing a strategy for counteracting immunotherapeutic resistance in HCC.
gastroenterology & hepatology